CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced that on May 13, 2008, the United States Patent and Trademark Office granted U.S. Patent No. 7,371,515 covering AVEO’s Mammalian Second Site Suppressor (MaSS) screen technology for identifying small molecule and antibody targets functionally relevant to cancer cell proliferation and survival. This patent adds to the intellectual property surrounding AVEO’s proprietary and innovative cancer biology platform.
